Vol. 2 No. 3 (2022)
Reimbursement Reviews

Chlormethine Gel (Ledaga)

Published March 24, 2022

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses chlormethine gel (Ledaga), 160 mcg chlormethine per gram gel, in 60 g tubes, for topical application to the skin.
  • Indication Proposed: For the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma in adult patients.